Smart Nanoformulations for Precision Medicine: Emerging Technologies, Therapeutic Applications, and Clinical Challenges

Abstract

Smart nanoformulations have emerged as promising platforms in precision medicine by enabling controlled drug delivery, improved therapeutic targeting, enhanced bioavailability, and potential reductions in systemic toxicity. Conventional drug delivery systems often encounter limitations associated with poor aqueous solubility, rapid clearance, inadequate tissue penetration, nonspecific biodistribution, and interpatient variability. Recent advances have facilitated multifunctional carriers including polymeric nanoparticles, liposomes, lipid nanoparticles, dendrimers, mesoporous silica nanoparticles, metallic nanoparticles, and biomimetic nanocarriers. These systems can respond to endogenous stimuli such as pH, reactive oxygen species, enzyme activity, hypoxia, and redox conditions, or exogenous stimuli including light, magnetic fields, temperature, and ultrasound. Integration with artificial intelligence, molecular imaging, genomic profiling, and theranostics offers opportunities for personalized therapy. Applications span oncology, neurological and cardiovascular disorders, inflammation, infectious diseases, and nucleic acid therapeutics. Although several nanomedicines have achieved regulatory approval, most complex stimuliresponsive and patient-specific systems remain investigational. Critical obstacles include biological heterogeneity, limited tissue accumulation, protein corona formation, immunogenicity, long-term toxicity, manufacturing complexity, scale-up, and regulatory requirements. This review discusses major technologies, mechanisms, characterization approaches, therapeutic applications, clinical challenges, and future directions, emphasizing biomarker-guided patient selection and clinical feasibility.